The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma

Abstract

Chemotherapy has profoundly shaped modern oncology, evolving from early cytotoxic approaches to biologically informed strategies. In glioblastoma (GBM), the highly aggressive primary brain tumor, precision medicine does not rely on the identification of a single crucial oncogenic driver but integrates biologically informed stratification strategies to predict treatment response, resistance, and therapy-induced adaptation. This review recapitulates the historical milestones of chemotherapeutic development in neuro-oncology, with particular emphasis on GBM. As the main chemotherapeutic agent currently used in GBM, temozolomide (TMZ) initially represented a major therapeutic breakthrough; however, its clinical use has progressively unveiled the biological and clinical limitations of conventional cytotoxic paradigms. While TMZ exerts antitumor activity through DNA damage–induced apoptosis, accumulating experimental evidence indicates that it may also elicit adaptive responses, ultimately supporting tumor progression and therapy resistance. By integrating historical milestones with recent molecular understanding, this review highlights how improved knowledge of therapy-induced adaptations may inform emerging precision medicine strategies in GBM, underscoring the need for tailored treatments to overcome tumor heterogeneity and adaptive responses.

Keywords

glioblastoma / chemoresistance / temozolomide / tumor microenvironment / precision medicine

References

[1] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114: 97-109.

[2] Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17: 98-110.

[3] Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131: 803-20.

[4] Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23: 1231-51.

[5] Teraiya M, Perreault H, Chen VC. An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance? Front Oncol. 2023; 13: 1166207.

[6] Munoz JL, Walker ND, Scotto KW, Rameshwar P. Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells. Cancer Lett. 2015; 367: 69-75.

[7] Xu X, Zheng Y, Luo L, You Z, Chen H, Wang J, et al. Glioblastoma stem cells deliver ABCB4 transcribed by ATF3 via exosomes conferring glioblastoma resistance to temozolomide. Cell Death Dis. 2024; 15: 318.

[8] Hotchkiss KM, Sampson JH. Temozolomide treatment outcomes and immunotherapy efficacy in brain tumor. J Neurooncol. 2021; 151: 55-62.

[9] Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 2018; 20: 1566-72.

[10] Zhang L, Wang Z, Liu K, Liu Y, Wang S, Jiang W, et al. Targets of tumor microenvironment for potential drug development. MedComm - Oncology. 2024; 3: e68.

[11] Kettenmann H, Ugursu B, Ransom BR, Steinhäuser C. The Concept of Neuroglia - the State of the Art Circa 1900. Glia. 2025; 73: 890-904.

[12] MacKenzie DJ. A Classification of the Tumours of the Glioma Group on a Histogenetic Basis With a Correlated Study of Prognosis. Can Med Assoc J. 1926; 16: 872.

[13] Kirkpatrick DB. The first primary brain-tumor operation. J Neurosurg. 1984; 61: 809-13.

[14] Tan T, Black PM. Sir Victor Horsley (1857-1916): pioneer of neurological surgery. Neurosurgery. 2002; 50: 607-11: discussion 611.

[15] Uluc K, Kujoth GC, Baskaya MK, Bergman W. Operating microscopes: past, present, and future. Neurosurg Focus. 2009; 27: E4.

[16] Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. JAMA Oncol. 2020; 6: 495-503.

[17] Röntgen WC. ON A NEW KIND OF RAYS. Science. 1896; 3: 227-31.

[18] Ishaque M, Wallace DJ, Grandhi R. Pneumoencephalography in the workup of neuropsychiatric illnesses: a historical perspective. Neurosurg Focus. 2017; 43: E10.

[19] Artico M, Spoletini M, Fumagalli L, Biagioni F, Ryskalin L, Fornai F, et al. Egas Moniz: 90 Years (1927-2017) from Cerebral Angiography. Front Neuroanat. 2017; 11: 81.

[20] Dillon WP. 50th anniversary of computed tomography: past and future applications in clinical neuroscience. J Med Imaging (Bellingham). 2021; 8: 052112.

[21] Lauterbur PC. Image formation by induced local interactions. Examples employing nuclear magnetic resonance. 1973. Clin Orthop Relat Res. 1989; 3-6.

[22] Martucci M, Russo R, Schimperna F, D’Apolito G, Panfili M, Grimaldi A, et al. Magnetic Resonance Imaging of Primary Adult Brain Tumors: State of the Art and Future Perspectives. Biomedicines. 2023; 11: 364.

[23] Bernstock JD, Gary SE, Klinger N, Valdes PA, Essayed WI, Olsen HE, et al. Standard clinical approaches and emerging modalities for glioblastoma imaging. Neurooncol Adv. 2022; 4: vdac080.

[24] Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. 2021; 18: 170-86.

[25] Overcast WB, Davis KM, Ho CY, Hutchins GD, Green MA, Graner BD, et al. Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors. Curr Oncol Rep. 2021; 23: 34.

[26] Abbasi IA, Alshehri M, AlQahtani Y. Tumor-specific PET tracer imaging and contrast-enhanced Mri based tumor volume differences inspection of glioblastoma patients. Sci Rep. 2025; 15: 30011.

[27] Hönikl LS, Delbridge C, Yakushev I, Negwer C, Bernhardt D, Schmidt-Graf F, et al. Assessing the role of FET-PET imaging in glioblastoma recurrence: A retrospective analysis of diagnostic accuracy. Brain Spine. 2025; 5: 105599.

[28] Kogias E, Fotakopoulos G, Georgakopoulou VE, Kagkouras I, Spandidos DA, Trakas N, et al. 5-ALA vs. fluorescein guided resection for high-grade gliomas: A systematic review and meta-analysis. Mol Clin Oncol. 2026; 24: 18.

[29] GILMAN A. The initial clinical trial of nitrogen mustard. Am J Surg. 1963; 105: 574-8.

[30] Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978; 49: 333-43.

[31] Thomas RP, Recht L, Nagpal S. Advances in the management of glioblastoma: the role of temozolomide and MGMT testing. Clin Pharmacol. 2013; 5: 1-9.

[32] Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997; 23: 35-61.

[33] Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 1987; 47: 5846-52.

[34] Jiapaer S, Furuta T, Tanaka S, Kitabayashi T, Nakada M. Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma. Neurol Med Chir (Tokyo). 2018; 58: 405-21.

[35] Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al.; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987-96.

[36] Qi X, Jha SK, Jha NK, Dewanjee S, Dey A, Deka R, et al. Antioxidants in brain tumors: current therapeutic significance and future prospects. Mol Cancer. 2022; 21: 204.

[37] Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, et al. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004; 10: 3728-36.

[38] Patel M, McCully C, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol. 2003; 61: 203-7.

[39] Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017; 28: 1457-72.

[40] Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004; 22: 133-42.

[41] Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst. 2005; 97: 880-7.

[42] Ma Y, Wang Y, Nie C, Lin Y. The efficacy of targeted therapy combined with radiotherapy and temozolomide-based chemotherapy in the treatment of glioma: A systemic review and meta-analysis of phase II/III randomized controlled trials. Front Oncol. 2023; 13: 1082539.

[43] Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019; 393: 678-88.

[44] Ortiz R, Perazzoli G, Cabeza L, Jiménez-Luna C, Luque R, Prados J, et al. Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Curr Neuropharmacol. 2021; 19: 513-37.

[45] Zhong L, Yang P, Zhang C, Wang Z, Jiang T, Chen B, et al. Long-term adjuvant administration of temozolomide impacts serum ions concentration in high-grade glioma. Chin Neurosurg J. 2022; 8: 6.

[46] Kaina B. Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications. J Clin Med. 2023; 12: 7442.

[47] Aasland D, Götzinger L, Hauck L, Berte N, Meyer J, Effenberger M, et al. Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. Cancer Res. 2019; 79: 99-113.

[48] Stratenwerth B, Geisen SM, He Y, Beltzig L, Sturla SJ, Kaina B. Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. Mol Cancer Ther. 2021; 20: 1789-99.

[49] Christmann M, Kaina B. Epigenetic regulation of DNA repair genes and implications for tumor therapy. Mutat Res Rev Mutat Res. 2019; 780: 15-28.

[50] Zhao H, Wang S, Song C, Zha Y, Li L. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients’ survival: a meta-analysis. World J Surg Oncol. 2016; 14: 261.

[51] Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352: 997-1003.

[52] Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021; 4: 17-43.

[53] Gibson D, Ravi A, Rodriguez E, Chang S, Bush NO, Taylor J, et al. Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect. Neurooncol Adv. 2023; 5: vdad115.

[54] Lang F, Liu Y, Chou F, Yang C. Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 2021; 228: 107922.

[55] Jezierzański M, Nafalska N, Stopyra M, Furgoł T, Miciak M, Kabut J, et al. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme-A Literature Review and Clinical Outcomes. Curr Oncol. 2024; 31: 3994-4002.

[56] Kaina B. Temozolomide in Glioblastoma Therapy: Role of Apoptosis, Senescence and Autophagy. Biomedicines. 2019; 7: 90.

[57] He Y, Kaina B. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? Int J Mol Sci. 2019; 20: 1562.

[58] Li G, Zhang H, Liu Y, Kong L, Guo Q, Jin F. Effect of temozolomide on livin and caspase-3 in U251 glioma stem cells. Exp Ther Med. 2015; 9: 744-50.

[59] Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O⁶-methylguanine. Oncogene. 2007; 26: 186-97.

[60] Karachi A, Yang C, Dastmalchi F, Sayour EJ, Huang J, Azari H, et al. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition. Neuro Oncol. 2019; 21: 730-41.

[61] Lombardi F, Augello FR, Artone S, Ciafarone A, Topi S, Cifone MG, et al. Involvement of Cyclooxygenase-2 in Establishing an Immunosuppressive Microenvironment in Tumorspheres Derived from TMZ-Resistant Glioblastoma Cell Lines and Primary Cultures. Cells. 2024; 13: 258.

[62] Panzarini E, Tacconi S, Carata E, Mariano S, Tata AM, Dini L. Molecular Characterization of Temozolomide-Treated and Non Temozolomide-Treated Glioblastoma Cells Released Extracellular Vesicles and Their Role in the Macrophage Response. Int J Mol Sci. 2020; 21: 8353.

[63] Heynckes S, Daka K, Franco P, Gaebelein A, Frenking JH, Doria-Medina R, et al. Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme. BMC Cancer. 2019; 19: 117.

[64] Lombardi F, Augello FR, Artone S, Ayroldi E, Giusti I, Dolo V, et al. Cyclooxygenase-2 Upregulated by Temozolomide in Glioblastoma Cells Is Shuttled In Extracellular Vesicles Modifying Recipient Cell Phenotype. Front Oncol. 2022; 12: 933746.

[65] Auffinger B, Tobias AL, Han Y, Lee G, Guo D, Dey M, et al. Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ. 2014; 21: 1119-31.

[66] Feldheim J, Kessler AF, Feldheim JJ, Schulz E, Wend D, Lazaridis L, et al. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. Int J Mol Sci. 2022; 23: 5238.

[67] Gao X, Zang J, Zheng M, Zhang Y, Yue K, Cao X, et al. Temozolomide Treatment Induces HMGB1 to Promote the Formation of Glioma Stem Cells via the TLR2/NEAT1/Wnt Pathway in Glioblastoma. Front Cell Dev Biol. 2021; 9: 620883.

[68] Lee G, Auffinger B, Guo D, Hasan T, Deheeger M, Tobias AL, et al. Dedifferentiation of Glioma Cells to Glioma Stem-like Cells By Therapeutic Stress-induced HIF Signaling in the Recurrent GBM Model. Mol Cancer Ther. 2016; 15: 3064-76.

[69] Liu B, Zhou J, Wang C, Chi Y, Wei Q, Fu Z, et al. LncRNA SOX2OT promotes temozolomide resistance by elevating SOX2 expression via ALKBH5-mediated epigenetic regulation in glioblastoma. Cell Death Dis. 2020; 11: 384.

[70] Palumbo P, Miconi G, Cinque B, Lombardi F, Torre CL, Dehcordi SR, et al. NOS2 expression in glioma cell lines and glioma primary cell cultures: correlation with neurosphere generation and SOX-2 expression. Oncotarget. 2017; 8: 25582-98.

[71] Valtorta S, Dico AL, Raccagni I, Gaglio D, Belloli S, Politi LS, et al. Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models. Oncotarget. 2017; 8: 113090-104.

[72] André-Grégoire G, Bidère N, Gavard J. Temozolomide affects Extracellular Vesicles Released by Glioblastoma Cells. Biochimie. 2018; 155: 11-5.

[73] Kıyga E, Adıgüzel Z, Önay Uçar E. Temozolomide increases heat shock proteins in extracellular vesicles released from glioblastoma cells. Mol Biol Rep. 2022; 49: 8701-13.

[74] Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O⁶-alkylating agents in human glioblastomas. J Clin Oncol. 2006; 24: 274-87.

[75] Caporali S, Levati L, Graziani G, Muzi A, Atzori MG, Bonmassar E, et al. NF-κB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. J Transl Med. 2012; 10: 252.

[76] Kasuga C, Ebata T, Kayagaki N, Yagita H, Hishii M, Arai H, et al. Sensitization of human glioblastomas to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by NF-kappaB inhibitors. Cancer Sci. 2004; 95: 840-4.

[77] Lombardi F, Augello FR, Artone S, Gugu MK, Cifone MG, Cinque B, et al. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Int J Mol Sci. 2022; 23: 1545.

[78] Pinevich AA, Bode II, Vartanyan NL, Kiseleva LN, Kartashev AV, Samoilovich MP. Temozolomide-Resistant Human T2 and T98G Glioblastoma Cells. Cell Tiss Biol. 2022; 16: 339-51.

[79] Beltzig L, Schwarzenbach C, Leukel P, Frauenknecht KBM, Sommer C, Tancredi A, et al. Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers (Basel). 2022; 14: 2233.

[80] Chang K, Hsu T, Hsu C, Tsai S, Liu J, Chou S, et al. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O⁶-methylguanine-DNA methyltransferase. Redox Biol. 2017; 13: 655-64.

[81] Chuang H, Hsu L, Pan C, Pikatan NW, Yadav VK, Fong I, et al. The E3 Ubiquitin Ligase NEDD4-1 Mediates Temozolomide-Resistant Glioblastoma through PTEN Attenuation and Redox Imbalance in Nrf2-HO-1 Axis. Int J Mol Sci. 2021; 22: 10247.

[82] Günther W, Pawlak E, Damasceno R, Arnold H, Terzis AJ. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer. 2003; 88: 463-9.

[83] Hirose Y, Katayama M, Mirzoeva OK, Berger MS, Pieper RO. Akt activation suppresses Chk2-mediated, methylating agent-induced G2 arrest and protects from temozolomide-induced mitotic catastrophe and cellular senescence. Cancer Res. 2005; 65: 4861-9.

[84] Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski K, Christmann M, et al. Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS One. 2013; 8: e55665.

[85] Lin C, Lee C, Shih Y, Lin C, Wang S, Chen T, et al. Inhibition of mitochondria- and endoplasmic reticulum stress-mediated autophagy augments temozolomide-induced apoptosis in glioma cells. PLoS One. 2012; 7: e38706.

[86] Ma L, Liu J, Zhang X, Qi J, Yu W, Gu Y. p38 MAPK-dependent Nrf2 induction enhances the resistance of glioma cells against TMZ. Med Oncol. 2015; 32: 69.

[87] Nakajima S, Kitamura M. Bidirectional regulation of NF-κB by reactive oxygen species: a role of unfolded protein response. Free Radic Biol Med. 2013; 65: 162-74.

[88] Rocha CRR, Kajitani GS, Quinet A, Fortunato RS, Menck CFM. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells. Oncotarget. 2016; 7: 48081-92.

[89] Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009; 29: 1-42.

[90] Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, et al. Immune Checkpoint in Glioblastoma: Promising and Challenging. Front Pharmacol. 2017; 8: 242.

[91] Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27: 4733-40.

[92] Ram Z, Kim C, Hottinger AF, Idbaih A, Nicholas G, Zhu J. Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial. Front Oncol. 2021; 11: 671972.

[93] Okura H, Smith CA, Rutka JT. Gene therapy for malignant glioma. Mol Cell Ther. 2014; 2: 21.

[94] Rayati M, Mansouri V, Ahmadbeigi N. Gene therapy in glioblastoma multiforme: Can it be a role changer? Heliyon. 2024; 10: e27087.

[95] Begagić E, Bečulić H, Đuzić N, Džidić-Krivić A, Pugonja R, Muharemović A, et al. CRISPR/Cas9-Mediated Gene Therapy for Glioblastoma: A Scoping Review. Biomedicines. 2024; 12: 238.

[96] Lucifero AG, Luzzi S, Brambilla I, Guarracino C, Mosconi M, Foiadelli T, et al. Gene therapies for high-grade gliomas: from the bench to the bedside. Acta Biomed. 2020; 91: 32-50.

[97] An Z, Aksoy O, Zheng T, Fan Q, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018; 37: 1561-75.

[98] Haque S, Morris JC. Transforming growth factor-β: A therapeutic target for cancer. Hum Vaccin Immunother. 2017; 13: 1741-50.

[99] Osher E, Macaulay VM. Therapeutic Targeting of the IGF Axis. Cells. 2019; 8: 895.

[100] Trojan A, Lone Y, Briceno I, Trojan J. Anti-Gene IGF-I Vaccines in Cancer Gene Therapy: A Review of a Case of Glioblastoma. Curr Med Chem. 2024; 31: 1983-2002.

[101] Luksik AS, Yazigi E, Shah P, Jackson CM. CAR T Cell Therapy in Glioblastoma: Overcoming Challenges Related to Antigen Expression. Cancers (Basel). 2023; 15: 1414.

[102] Heckman-Stoddard BM, Smith JJ. Precision medicine clinical trials: defining new treatment strategies. Semin Oncol Nurs. 2014; 30: 109-16.

[103] Micheletti C, Bonetti G, Madeo G, Gadler M, Benedetti S, Guerri G, et al. Omics sciences and precision medicine in glioblastoma. Clin Ter. 2023; 174: 77-84.

[104] Reed MR, Lyle AG, Loose AD, Maddukuri L, Learned K, Beale HC, et al. A Functional Precision Medicine Pipeline Combines Comparative Transcriptomics and Tumor Organoid Modeling to Identify Bespoke Treatment Strategies for Glioblastoma. Cells. 2021; 10: 3400.

[105] Iyer K, Saini S, Bhadra S, Kulavi S, Bandyopadhyay J. Precision medicine advancements in glioblastoma: A systematic review. Biomedicine (Taipei). 2023; 13: 1-13.

[106] Weller J, Potthoff A, Zeyen T, Schaub C, Duffy C, Schneider M, et al. Current status of precision oncology in adult glioblastoma. Mol Oncol. 2024; 18: 2927-50.

[107] Yates LR, Seoane J, Tourneau CL, Siu LL, Marais R, Michiels S, et al. The European Society for Medical Oncology (ESMO) Precision Medicine Glossary. Ann Oncol. 2018; 29: 30-5.

[108] Garralda E, Dienstmann R, Piris-Giménez A, Braña I, Rodon J, Tabernero J. New clinical trial designs in the era of precision medicine. Mol Oncol. 2019; 13: 549-57.

[109] Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med. 2017; 377: 62-70.

[110] Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2011; 9: 199-207.

[111] Joo KM, Jin J, Kim E, Kim KH, Kim Y, Kang BG, et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012; 72: 3828-38.

[112] Sarkaria JN. A precision medicine umbrella trial to nominate promising therapies for glioblastoma. Neuro Oncol. 2026; 28: 3-4.

[113] Lim M, Berry D, Berry N, Colman H, de Groot J, Ellingson B, et al. TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. Neuro-Oncol. 2025; 27: v422.

[114] Bhaskaran D, Savage J, Patel A, Collinson F, Mant R, Boele F, et al. A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer. 2024; 24: 83.

[115] Javid FA, Belancic A, Kwok MK, Lam YW. Recent Advances in the Therapeutic Potential of Cannabinoids Against Gliomas: A Systematic Review (2022-2025). Pharmacol Res Perspect. 2025; 13: e70160.

[116] Davy M, Genest L, Legrand C, Pelouin O, Froget G, Castagné V, et al. Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models. Cancers. 2023; 15: 4478.

[117] Gherardini L, Vetri Buratti V, Maturi M, Inzalaco G, Locatelli E, Sambri L, et al. Loco-regional treatment with temozolomide-loaded thermogels prevents glioblastoma recurrences in orthotopic human xenograft models. Sci Rep. 2023; 13: 4630.

[118] Guo G, Gong K, Puliyappadamba VT, Panchani N, Pan E, Mukherjee B, et al. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. Neuro-Oncol. 2019; 21: 1529-39.

[119] Liu F, Zhou Q, Jiang HF, Zhang TT, Miao C, Xu XH, et al. Piperlongumine conquers temozolomide chemoradiotherapy resistance to achieve immune cure in refractory glioblastoma via boosting oxidative stress-inflamation-CD8+-T cell immunity. J Exp Clin Cancer Res. 2023; 42: 118.

[120] Minea RO, Thein TZ, Yang Z, Campan M, Ward PM, Schönthal AH, et al. NEO212, temozolomide conjugated to NEO100, exerts superior therapeutic activity over temozolomide in preclinical chemoradiation models of glioblastoma. Neuro-Oncol Adv. 2024; 6: vdae095.

[121] Oraiopoulou ME, Tzamali E, Psycharakis SE, Tzedakis G, Makatounakis T, Manolitsi K, et al. The Temozolomide-Doxorubicin paradox in Glioblastoma in vitro-in silico preclinical drug-screening. Sci Rep. 2024; 14: 3759.

[122] Watanabe F, Hollingsworth EW, Bartley JM, Wisehart L, Desai R, Hartlaub AM, et al. Patient-derived organoids recapitulate glioma-intrinsic immune program and progenitor populations of glioblastoma. PNAS Nexus. 2024; 3: pgae051.

[123] Wei Y, Wang P, Zhao J, Fan X, Jiang J, Mu X, et al. Overexpression of miR-124 enhances the therapeutic benefit of TMZ treatment in the orthotopic GBM mice model by inhibition of DNA damage repair. Cell Death Dis. 2025; 16: 47.

[124] Basso J, Matos AM, Ghavami S, Fortuna A, Vitorino R, Vitorino C. Are we better together? Addressing a combined treatment of pitavastatin and temozolomide for brain cancer. Eur J Pharmacol. 2024; 985: 177087.

[125] Breen WG, Dixon JG, Anderson SK, Sarkaria JN, Brown PD, Yan ES, et al. Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastoma. Neuro-Oncol. 2025; 27: 2661-70.

[126] Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, et al. Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study. Med. 2025; 6: 100708.

[127] Geurts M, Berchtold L, Koenig F, Nabors B, Reardon DA, Tonn JC, et al. Temozolomide chemotherapy for patients with newly diagnosed glioblastoma in the CENTRIC EORTC 26071-22072 and CORE trials: Does time of administration matter? Neuro-Oncol Pract. 2025; 12: 291-300.

[128] Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, et al. Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas. JAMA Netw Open. 2023; 6: e2253285.

[129] Halatsch ME, Dwucet A, Schmidt CJ, Mühlnickel J, Heiland T, Zeiler K, et al. In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma. Pharmaceuticals. 2021; 14: 1241.

[130] Halatsch ME, Kast RE, Karpel-Massler G, Mayer B, Zolk O, Schmitz B, et al. A phase Ib/IIa trial of 9 repurposed drugs combined with temozolomide for the treatment of recurrent glioblastoma: CUSP9v3. Neuro-Oncol Adv. 2021; 3: vdab075.

[131] Lee EQ, Alexander BM, Romo CG, Supko JG, Agar NYR, Talebi Z, et al. Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Clin Cancer Res. 2025; 31: 983-92.

[132] Zeyen T, Treiber A, Schneider M, Potthoff AL, Schaub C, Roever L, et al. Second-line temozolomide in first recurrent MGMT-methylated glioblastoma after lomustine/temozolomide: Efficacy and safety. Neuro-Oncol Adv. 2025; 7: vdaf084.